Wall Street Journal
November 8, 2019
Two recent commentaries by biotechnology industry insiders highlighted a divide among venture capitalists: those who see artificial intelligence powering a revolution in drug discovery, and those who don’t.
Venture firms have financed several startups applying AI to drug discovery, including Recursion Pharmaceuticals Inc., Atomwise Inc., and twoXAR Inc., betting the technology will help uncover a new generation of novel medicines.
To read more, click here.